Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in early prostate cancer on active surveillance
NCT05191680Phase 2Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2023
- Primary completion
- Oct 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Apr 2023; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05191680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191680.